设为首页 加入收藏

TOP

Zometa 4 mg powder and solvent for solution for infusion Zol
2014-02-18 22:00:22 来源: 作者: 【 】 浏览:382次 评论:0

For doctors

 

What is it and how is it used?

The active substance in Zometa is zoledronic acid, which belongs to a group of substances called bisphosphonates. Zoledronic acid works by attaching itself to the bone and slowing down the rate of bone change. It is used:

What do you have to consider before using it?

Follow carefully all instructions given to you by your doctor.

Your doctor will carry out blood tests before you start treatment with Zometa and will check your response to treatment at regular intervals.

You should not be given Zometa:

Before you are given Zometa, tell your doctor:

Using other medicines
Please tell your doctor if you are taking or have recently taken any other medicines, including medicines obtained without a prescription. It is especially important that you tell your doctor if you are also taking:
– Aminoglycosides (medicines used to treat severe infections), since the combination of these with bisphosphonates may cause the calcium level in the blood to become too low. – Thalidomide or any other medicines which may harm your kidneys.

Patients aged 65 years and over
Zometa can be given to people aged 65 years and over. There is no evidence to suggest that any extra precautions are needed.

Use in children
There have been 2 studies on the use of Zometa in children with severe osteogenesis imperfecta (a genetic disorder, also called “brittle bone disease”). However, it has not been established whether these children will benefit from Zometa treatment.

Pregnancy and breast-feeding
You should not be given Zometa if you are pregnant. Tell your doctor if you are or think that you may be pregnant.

You must not be given Zometa if you are breast-feeding.

Ask your doctor for advice before taking any medicine while you are pregnant or breast-feeding.

Driving and using machines
The effects of Zometa on driving, using machines and performing other tasks that need your full attention have not been studied. However, there have been very rare cases of drowsiness with the use of Zometa. You should therefore be careful when driving, using machinery or performing other tasks that need full attention.

How is it used?

How much Zometa is given
– The usual single dose given is 4 mg.
– If you have a kidney problem, your doctor will give you a lower dose depending on the severity of your kidney problem.

How Zometa is given
– Zometa is given as a drip (infusion) into a vein which should take at least 15 minutes and should be administered as a single intravenous solution in a separate infusion line.

Patients whose blood calcium levels are not too high will also be prescribed calcium and vitamin D supplements to be taken each day.

How often you will be given Zometa
– If you are being treated for bone metastases, you will be given one infusion of Zometa every three to four weeks.
– If you are being treated to reduce the amount of calcium in your blood, you will normally only be given one infusion of Zometa.

If you are given more Zometa than you should be
If you have received doses higher than those recommended, you must be carefully monitored by your doctor. This is because you may develop serum electrolyte abnormalities (e.g. abnormal levels of calcium, phosphorus and magnesium) and/or changes in kidney function, including severe kidney impairment. If your level of calcium falls too low, you may have to be given supplemental calcium by infusion.

What are possible side effects?

Like all medicines, Zometa can cause side effects, although not everybody gets them. The most common ones are usually mild and will probably disappear after a short time.

The frequency of possible side effects listed below is defined using the following convention:

Tell your doctor about any of the following side effects as soon as possible:

Very common:

Common:

Uncommon:

Rare:

Very rare:

Irregular heart rhythm (atrial fibrillation) has been seen in patients receiving zoledronic acid for postmenopausal osteoporosis. It is currently unclear whether zoledronic acid causes this irregular heart rhythm but you should report it to your doctor if you experience such symptoms after you have received zoledronic acid.

If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor, nurse or pharmacist.

How should it be stored?

Your doctor, nurse or pharmacist knows how to store Zometa properly (see section 6).

↑ back to table of contents ↑

For doctors

What is it?

Zometa is a medicine that contains the active substance zoledronic acid. It is available as a powder and solvent, and as a concentrate, which are made up into a solution for infusion (drip into a vein).

What is it used for?

Zometa can be used to prevent bone complications in adults with advanced cancer that is affecting the bone. This includes fractures (breaks in the bone), spinal compression (when the spinal cord is compressed by the bone), bone disorders needing radiotherapy (treatment with radiation) or surgery, and hypercalcaemia (high levels of calcium in the blood). Zometa can also be used to treat the hypercalcaemia caused by tumours.
The medicine can only be obtained with a prescription.

How is it used?

Zometa must only be used by a doctor who has experience in the use of this type of medicine given into a vein.
The usual dose of Zometa is one infusion of 4 mg over at least 15 minutes. When used to prevent bone complications, the infusion can be repeated every three to four weeks, and patients should also take supplements of calcium and vitamin D. A lower dose is recommended for patients with bone metastases (when cancer has spread to the bone) if they have mild to moderate problems with their kidneys. It is not recommended for patients with severe kidney problems.

How does it work?

The active substance in Zometa, zoledronic acid, is a bisphosphonate. It stops the action of the osteoclasts, the cells in the body that are involved in breaking down the bone tissue. This leads to less bone loss. The reduction of bone loss helps to make bones less likely to break, which is useful in preventing fractures in cancer patients with bone metastases.
Patients with tumours can have high levels of calcium in their blood, released from the bones. By preventing the breakdown of bones, Zometa also helps to reduce the amount of calcium released into the blood.

How has it been studied?

Zometa has been studied in over 3,000 adults with bone metastases in three main studies looking at its ability to prevent bone damage. Zometa was compared with placebo (a dummy treatment) in two of the studies, and with pamidronate (another bisphosphonate) in the third. The main measure of effectiveness was the number of patients who developed at least one new ‘skeletal event’ over 13 months. This included any bone complications needing treatment with radiotherapy or surgery, any fractures or any spinal compression.
Zometa has also been compared with pamidronate in two main studies involving a total of 287 adults with hypercalcaemia caused by tumours. The main measure of effectiveness was the number of patients whose calcium levels had returned to normal within 10 days after treatment.

What benefits has it shown during the studies?

In the first two studies of patients with bone metastases, the number of patients who developed a new skeletal event was lower with Zometa (33 to 38%) than with placebo (44%). In the third study, Zometa was as effective as pamidronate: 44% of the patients receiving Zometa had at least one skeletal event, compared with 46% of those receiving pamidronate.
In patients with hypercalcaemia, Zometa was more effective than pamidronate. Looking at the results of the two studies together, 88% of the patients receiving Zometa had normal calcium levels within 10 days after treatment, compared with 70% of those receiving pamidronate.

What is the risk associated?

The most common side effect with Zometa (seen in more than 1 patient in 10) is hypophosphataemia (low blood phosphate levels). For the full list of all side effects reported with Zometa, see the Package Leaflet.
Zometa should not be used in people who may be hypersensitive (allergic) to zoledronic acid, other bisphosphonates or any of the other ingredients. Zometa should not be used in pregnant or breast-feeding women.

Why has it been approved?

The Committee for Medicinal Products for Human Use (CHMP) decided that Zometa’s benefits are greater than its risks and recommended that it be given marketing authorisation.

Further information

The European Commission granted a marketing authorisation valid throughout the European Union to Novartis Europharm Limited for Zometa on 20 March 2001. The marketing authorisation is valid for an unlimited period.

↑ back to table of contents ↑
 

Name

 

Zometa 4 mg powder and solvent for solution for infusion

 

Composition

 

One vial contains 4 mg zoledronic acid (anhydrous), corresponding to 4.264 mg zoledronic acid monohydrate.

For a full list of excipients, see section 6.1.

 

Pharmaceutical Form

 

Powder and solvent for solution for infusion

 

Are you an Healthcare Professional? Access professional drug leaflets on Diagnosia.com!

 

以下是“全球医药”详细资料
Tags: 责任编辑:admin
】【打印繁体】【投稿】【收藏】 【推荐】【举报】【评论】 【关闭】 【返回顶部
分享到QQ空间
分享到: 
上一篇Zometa 4 mg poudre et solvant p.. 下一篇Zometa 4 mg/5 ml concentrate fo..

相关栏目

最新文章

图片主题

热门文章

推荐文章

相关文章

广告位